PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Li, Z.* ; Sun, G.* ; Sun, G.* ; Cheng, Y.* ; Wu, L.* ; Wang, Q. ; Lv, C.* ; Zhou, Y.* ; Xia, Y.* ; Tang, W.*

Various uses of PD1/PD-L1 inhibitor in oncology: Opportunities and challenges.

Front. Oncol. 11:771335 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune function of the body, and ultimately achieves the goal of controlling tumor cells.With the in-depth understanding of tumor immune escape mechanism and tumor microenvironment, and the in-depth study of tumor immunotherapy, immune checkpoint inhibitors represented by Programmed Death 1/Programmed cell Death-Ligand 1(PD-1/PD-L1) inhibitors are becoming increasingly significant in cancer medication treatment. employ a variety of ways to avoid detection by the immune system, a single strategy is not more effective in overcoming tumor immune evasion and metastasis. Combining different immune agents or other drugs can effectively address situations where immunotherapy is not efficacious, thereby increasing the chances of success and alternative access to alternative immunotherapy. Immune combination therapies for cancer have become a hot topic in cancer treatment today. In this paper, several combination therapeutic modalities of PD1/PD-L1 inhibitors are systematically reviewed. Finally, an analysis and outlook are provided in the context of the recent advances in combination therapy with PD1/PD-L1 inhibitors and the pressing issues in this field.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
6.244
1.251
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Pd-1/pd-l1 Inhibitors ; Cancer ; Drug Combination Therapy ; Immunotherapy ; Tumor Microenvironment; Regulates Pd-1 Expression; Cd8(+) T-cells; Endothelial Growth-factor; Nf-kappa-b; Breast-cancer; Tumor Microenvironment; Antitumor Immunity; Targeted Therapy; Hodgkin Lymphoma; Dendritic Cells
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 2234-943X
e-ISSN 2234-943X
Zeitschrift Frontiers in Oncology
Quellenangaben Band: 11, Heft: , Seiten: , Artikelnummer: 771335 Supplement: ,
Verlag Frontiers
Verlagsort Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-500390-001
Förderungen China Scholarship Council (CSC)
National Natural Science Foundation of China
DOI 10.3389/fonc.2021.771335
WOS ID WOS:000741402100001
Scopus ID 85120544298
PubMed ID 34869005
Erfassungsdatum 2022-02-01
[➜Korrektur melden]